Weston Brain Institute Rapid Response Biomarkers program – LOI
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire with unit
Memorial Deadline: RIS Review not required for LOI
External Deadline: Tuesday 17th, March 2026
Description
Letter of Intent deadline: March 17, 2026, at 2:00pm ET
The Rapid Response program provides seed funding to identify and validate novel, high-risk, high-reward solutions for neurodegenerative diseases of aging (NDAs) that exhibit a high-potential to enhance patient outcomes and quality of life in a real-world context.
Eligible projects should meet the following criteria:
-
- – Be translational/applied research that can accelerate the validation to clinical implementation of biological, functional, and digital biomarkers for NDAs, with a preference for, but not limited to, enabling early detection and timely and accurate diagnosis of dementia.
– Biomarkers must address unmet needs in the staging, prognosis, diagnosis, monitoring of disease progression, and differentiation of NDAs. - – Projects should enable the development of biomarkers from the validation stage forward.
– Prioritize approaches that are scalable, minimally invasive, and feasible for implementation across diverse settings.
- – Be translational/applied research that can accelerate the validation to clinical implementation of biological, functional, and digital biomarkers for NDAs, with a preference for, but not limited to, enabling early detection and timely and accurate diagnosis of dementia.
- – Have preliminary data to support the rationale, hypothesis, and feasibility of the project.
See here for more information.
Important dates:
- Program Information Webinar (session 1): February 3, 2026, at 1pm ET – Register here
- Program Information Webinar (session 2): February 17, 2026, at 1pm ET – Register here
- Letter of Intent deadline: March 17, 2026, at 2pm ET
- Proposal Deadline: August 4, 2026
- Award announcement: November 2026